{"id":226633,"date":"2026-10-02T22:35:48","date_gmt":"2026-10-03T02:35:48","guid":{"rendered":"https:\/\/fightcolorectalcancer.org\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/"},"modified":"2026-10-26T11:30:05","modified_gmt":"2026-10-26T15:30:05","slug":"impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept","status":"publish","type":"post","link":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/","title":{"rendered":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT"},"content":{"rendered":"<div>\n<p>Gut. 1 de octubre de 2026: gutjnl-2026-339167. doi: 10.1136\/gutjnl-2026-339167. Publicado en l\u00ednea antes de su impresi\u00f3n.<\/p>\n<p><b>RESUMEN<\/b><\/p>\n<p>ANTECEDENTES: El impacto de la detecci\u00f3n del ADN tumoral circulante (ADNtc), que permite evaluar la enfermedad residual m\u00ednima (ERM) tras un tratamiento curativo, sigue siendo objeto de debate, sobre todo en el caso de los pacientes en estadio IV.<\/p>\n<p>OBJETIVO: Los objetivos del estudio eran evaluar el papel pron\u00f3stico de la MRD y calcular el tiempo de anticipaci\u00f3n (LT) en distintos momentos al realizar pruebas longitudinales de MRD.<\/p>\n<p>DISE\u00d1O: INTERCEPT es un estudio de cohorte prospectivo y observacional en el que participan pacientes con c\u00e1ncer colorrectal en estadios II-IV que reciben tratamiento con intenci\u00f3n curativa y a los que se realiza un seguimiento longitudinal mediante an\u00e1lisis de MRD basados en muestras de tejido, como parte de la atenci\u00f3n cl\u00ednica habitual.<\/p>\n<p>RESULTADOS: Los resultados del estudio confirman el valor pron\u00f3stico de la MRD, incluso m\u00e1s all\u00e1 de los 12 meses tras la cirug\u00eda, con una mayor incidencia de recidiva en los pacientes en estadio II-III con MRD positiva que en los pacientes en estadio IV con MRD negativa (p < 0,0001). El tratamiento adyuvante en la enfermedad en estadio IV mostr\u00f3 un beneficio duradero limitado tanto en pacientes con MRD positiva como en los que la ten\u00edan negativa. El manejo cl\u00ednico se asoci\u00f3 a un mayor uso de t\u00e9cnicas de imagen de segunda l\u00ednea m\u00e1s intensivas (resonancia magn\u00e9tica, tomograf\u00eda por emisi\u00f3n de positrones; p < 0,0001) cuando se detectaba ctDNA. Se observ\u00f3 la detecci\u00f3n simult\u00e1nea de enfermedad macrosc\u00f3pica en el 26 % de los casos y, al excluirla, el tiempo de supervivencia (LT) desde la detecci\u00f3n de la MRD hasta la recurrencia radiogr\u00e1fica var\u00eda durante el seguimiento (p = 0,007). Las pruebas en m\u00faltiples momentos mejoran la sensibilidad para detectar la recurrencia (79,9 % frente a 48,5 %) y pueden permitir intervenciones m\u00e1s tempranas y potencialmente curativas.    <\/p>\n<p>CONCLUSI\u00d3N: Las pruebas de ADN libre circulante (ctDNA) ofrecen un marco para la estratificaci\u00f3n del riesgo y definen ventanas temporales que pueden servir de base para futuras estrategias de intervenci\u00f3n. Se necesitan estudios prospectivos de intervenci\u00f3n para definir su utilidad cl\u00ednica y la forma \u00f3ptima de aplicarlas. <\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42823331\/?utm_source=SimplePie&#038;utm_medium=rss&#038;utm_campaign=pubmed-2&#038;utm_content=1zCzv8cgXYLTFpYKqcnmEQSRKKzgHYU2epGXR7qqB04ouFsEtP&#038;fc=20260305170338&#038;ff=20261002223547&#038;v=2.20.1\">42823331<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1136\/gutjnl-2026-339167\">10.1136\/gutjnl-2026-339167<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Gut. 1 de octubre de 2026: gutjnl-2026-339167. doi: 10.1136\/gutjnl-2026-339167. Publicado en l\u00ednea antes de su impresi\u00f3n. RESUMEN ANTECEDENTES: El impacto de la detecci\u00f3n del ADN tumoral circulante (ADNtc), que permite evaluar la enfermedad residual m\u00ednima (ERM) tras un tratamiento curativo, sigue siendo objeto de debate, sobre todo en el caso de los pacientes en estadio [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[633],"tags":[],"class_list":["post-226633","post","type-post","status-publish","format-standard","hentry","category-investiga"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Gut. 1 de octubre de 2026: gutjnl-2026-339167. doi: 10.1136\/gutjnl-2026-339167. Publicado en l\u00ednea antes de su impresi\u00f3n. RESUMEN ANTECEDENTES: El impacto de la detecci\u00f3n del ADN tumoral circulante (ADNtc), que permite evaluar la enfermedad residual m\u00ednima (ERM) tras un tratamiento curativo, sigue siendo objeto de debate, sobre todo en el caso de los pacientes en estadio [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/\" \/>\n<meta property=\"og:site_name\" content=\"Fight Colorectal Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FightCRC\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-03T02:35:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-26T15:30:05+00:00\" \/>\n<meta name=\"author\" content=\"IntegrityAdmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@fightcrc\" \/>\n<meta name=\"twitter:site\" content=\"@fightcrc\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"IntegrityAdmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/\"},\"author\":{\"name\":\"IntegrityAdmin\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#\\\/schema\\\/person\\\/4571279fec623734596590e5f3447adf\"},\"headline\":\"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT\",\"datePublished\":\"2026-10-03T02:35:48+00:00\",\"dateModified\":\"2026-10-26T15:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/\"},\"wordCount\":415,\"publisher\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#organization\"},\"articleSection\":[\"Investiga\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/\",\"url\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/\",\"name\":\"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#website\"},\"datePublished\":\"2026-10-03T02:35:48+00:00\",\"dateModified\":\"2026-10-26T15:30:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"P\u00e1gina de inicio\",\"item\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/pagina-de-inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/\",\"name\":\"Fight Colorectal Cancer\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#organization\",\"name\":\"Fight Colorectal Cancer\",\"url\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/e64f86851297bb53f096acdf76c859a294e23b96-1-1.png\",\"contentUrl\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/e64f86851297bb53f096acdf76c859a294e23b96-1-1.png\",\"width\":1265,\"height\":450,\"caption\":\"Fight Colorectal Cancer\"},\"image\":{\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/FightCRC\\\/\",\"https:\\\/\\\/x.com\\\/fightcrc\",\"https:\\\/\\\/www.instagram.com\\\/fightcrc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@FightCRC\",\"https:\\\/\\\/www.tiktok.com\\\/@fightcrc\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fight-colorectal-cancer\\\/\",\"https:\\\/\\\/bsky.app\\\/profile\\\/fightcrc.bsky.social\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/#\\\/schema\\\/person\\\/4571279fec623734596590e5f3447adf\",\"name\":\"IntegrityAdmin\",\"url\":\"https:\\\/\\\/fightcolorectalcancer.org\\\/es\\\/author\\\/integrityadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/","og_locale":"es_ES","og_type":"article","og_title":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer","og_description":"Gut. 1 de octubre de 2026: gutjnl-2026-339167. doi: 10.1136\/gutjnl-2026-339167. Publicado en l\u00ednea antes de su impresi\u00f3n. RESUMEN ANTECEDENTES: El impacto de la detecci\u00f3n del ADN tumoral circulante (ADNtc), que permite evaluar la enfermedad residual m\u00ednima (ERM) tras un tratamiento curativo, sigue siendo objeto de debate, sobre todo en el caso de los pacientes en estadio [&hellip;]","og_url":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/","og_site_name":"Fight Colorectal Cancer","article_publisher":"https:\/\/www.facebook.com\/FightCRC\/","article_published_time":"2026-10-03T02:35:48+00:00","article_modified_time":"2026-10-26T15:30:05+00:00","author":"IntegrityAdmin","twitter_card":"summary_large_image","twitter_creator":"@fightcrc","twitter_site":"@fightcrc","twitter_misc":{"Escrito por":"IntegrityAdmin","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/#article","isPartOf":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/"},"author":{"name":"IntegrityAdmin","@id":"https:\/\/fightcolorectalcancer.org\/es\/#\/schema\/person\/4571279fec623734596590e5f3447adf"},"headline":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT","datePublished":"2026-10-03T02:35:48+00:00","dateModified":"2026-10-26T15:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/"},"wordCount":415,"publisher":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/#organization"},"articleSection":["Investiga"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/","url":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/","name":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT - Fight Colorectal Cancer","isPartOf":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/#website"},"datePublished":"2026-10-03T02:35:48+00:00","dateModified":"2026-10-26T15:30:05+00:00","breadcrumb":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fightcolorectalcancer.org\/es\/impacto-clinico-de-las-pruebas-prospectivas-de-adn-tumoral-circulante-para-detectar-la-enfermedad-residual-minima-en-el-cancer-colorrectal-la-experiencia-del-programa-intercept\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"P\u00e1gina de inicio","item":"https:\/\/fightcolorectalcancer.org\/es\/pagina-de-inicio\/"},{"@type":"ListItem","position":2,"name":"Impacto cl\u00ednico de las pruebas prospectivas de ADN tumoral circulante para detectar la enfermedad residual m\u00ednima en el c\u00e1ncer colorrectal: la experiencia del programa INTERCEPT"}]},{"@type":"WebSite","@id":"https:\/\/fightcolorectalcancer.org\/es\/#website","url":"https:\/\/fightcolorectalcancer.org\/es\/","name":"Fight Colorectal Cancer","description":"","publisher":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fightcolorectalcancer.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/fightcolorectalcancer.org\/es\/#organization","name":"Fight Colorectal Cancer","url":"https:\/\/fightcolorectalcancer.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/fightcolorectalcancer.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/fightcolorectalcancer.org\/wp-content\/uploads\/2025\/10\/e64f86851297bb53f096acdf76c859a294e23b96-1-1.png","contentUrl":"https:\/\/fightcolorectalcancer.org\/wp-content\/uploads\/2025\/10\/e64f86851297bb53f096acdf76c859a294e23b96-1-1.png","width":1265,"height":450,"caption":"Fight Colorectal Cancer"},"image":{"@id":"https:\/\/fightcolorectalcancer.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/FightCRC\/","https:\/\/x.com\/fightcrc","https:\/\/www.instagram.com\/fightcrc\/","https:\/\/www.youtube.com\/@FightCRC","https:\/\/www.tiktok.com\/@fightcrc","https:\/\/www.linkedin.com\/company\/fight-colorectal-cancer\/","https:\/\/bsky.app\/profile\/fightcrc.bsky.social"]},{"@type":"Person","@id":"https:\/\/fightcolorectalcancer.org\/es\/#\/schema\/person\/4571279fec623734596590e5f3447adf","name":"IntegrityAdmin","url":"https:\/\/fightcolorectalcancer.org\/es\/author\/integrityadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/posts\/226633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/comments?post=226633"}],"version-history":[{"count":1,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/posts\/226633\/revisions"}],"predecessor-version":[{"id":226634,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/posts\/226633\/revisions\/226634"}],"wp:attachment":[{"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/media?parent=226633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/categories?post=226633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fightcolorectalcancer.org\/es\/wp-json\/wp\/v2\/tags?post=226633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}